Plasma B-cell activating factor levels and polymorphisms in hepatitis B-related hepatocellular carcinoma: Clinical correlation and prognosis.
暂无分享,去创建一个
N. Chuaypen | P. Tangkijvanich | N. Hirankarn | B. Sirichindakul | N. Pinjaroen | A. Khlaiphuengsin | Apichaya Khlaiphuengsin
[1] C. Recordati,et al. B lymphocytes limit senescence‐driven fibrosis resolution and favor hepatocarcinogenesis in mouse liver injury , 2018, Hepatology.
[2] T. Kanto,et al. Enhanced B‐cell differentiation driven by advanced cirrhosis resulting in hyperglobulinemia , 2018, Journal of gastroenterology and hepatology.
[3] M. Akkoyunlu,et al. The Role of BAFF System Molecules in Host Response to Pathogens , 2017, Clinical Microbiology Reviews.
[4] Zhengwen Liu,et al. Association of genetic variation in B-cell activating factor with chronic hepatitis B virus infection. , 2017, Immunology letters.
[5] Y. Jiao,et al. Hepatitis B Virus e Antigen Regulates Monocyte Function and Promotes B Lymphocyte Activation , 2017, Viral immunology.
[6] J. Roliński,et al. Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia , 2016, Tumor Biology.
[7] J. Muñóz-Valle,et al. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus , 2016, Lupus.
[8] A. Bertoletti,et al. Adaptive immunity in HBV infection. , 2016, Journal of hepatology.
[9] N. Terrault,et al. AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.
[10] B. Pulendran,et al. Liver fibrosis occurs through dysregulation of MyD88‐dependent innate B‐cell activity , 2015, Hepatology.
[11] M. Ayad,et al. Association of BAFF −871C/T Promoter Polymorphism with Hepatitis C-Related Mixed Cryoglobulinemia in a Cohort of Egyptian Patients , 2015, Molecular Diagnosis & Therapy.
[12] A. Lok,et al. Hepatitis B virus infection , 2014, The Lancet.
[13] Qianqian Zhu,et al. Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[14] M. Koutsilieris,et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. , 2014, Journal of autoimmunity.
[15] Y. Hiasa,et al. B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease , 2013, Hepatology International.
[16] Liwei Lu. Frontiers in B-cell immunology , 2012, Cellular and Molecular Immunology.
[17] F. Zlámal,et al. Circulating levels of B-cell activating factor in paediatric patients with malignancy with or without cancer-related cachexia. , 2012, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.
[18] I. Jacobson,et al. B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia , 2012, Clinical and experimental immunology.
[19] M. Alexandrakis,et al. B cell-activating factor: its clinical significance in multiple myeloma patients , 2012, Annals of Hematology.
[20] J. Bruix,et al. Hepatocellular carcinoma , 2012, The Lancet.
[21] A. Bertoletti,et al. Republished: Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection , 2011, Postgraduate Medical Journal.
[22] P. Caini,et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors. , 2011, Arthritis and rheumatism.
[23] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[24] A. Berstad,et al. Functional and Clinical Aspects of the B‐Cell‐Activating Factor (BAFF): A Narrative Review , 2011, Scandinavian journal of immunology.
[25] J. Cerhan,et al. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. , 2009, Cancer research.
[26] I. Choi,et al. Serum BAFF predicts prognosis better than APRIL in diffuse large B‐cell lymphoma patients treated with rituximab plus CHOP chemotherapy , 2008, European journal of haematology.
[27] A. P. Holt,et al. Attenuated liver fibrosis in the absence of B cells , 2006, Hepatology.
[28] T. Habermann,et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. , 2004, Blood.
[29] F. Mackay,et al. BAFF: A fundamental survival factor for B cells , 2002, Nature Reviews Immunology.
[30] V. Roschke,et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. , 2001, Arthritis and rheumatism.
[31] R. Groszmann,et al. American association for the study of liver diseases , 1992 .
[32] Z. Fatima,et al. Oncogenic Role of Tumor Viruses in Humans. , 2017, Viral immunology.
[33] C. Shih,et al. Increased percentage of B cells in patients with more advanced hepatocellular carcinoma. , 2010, Human immunology.
[34] D. Sène,et al. Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF). , 2007, Rheumatology.